AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2760597 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dynamic therapy
Number of subjects: 0
Study 331830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-nasal beclomethasone dipropionate
Number of subjects: 92
Study 31984781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intentions to complete the study
Number of subjects: 316
Study 31984781 — intervention group
Group type: EXPERIMENTAL
Intervention: High intentions to complete the study
Number of subjects: 316
Study 31984781 — intervention group
Group type: EXPERIMENTAL
Intervention: Income level
Number of subjects: 316
Study 31384338 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (0.075 mg IV)
Number of subjects: 165
Study 31384338 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (8 mg IV)
Number of subjects: 165
Study 31384338 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron (5 mg IV)
Number of subjects: 165
Study 26968329 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal working memory training
Number of subjects: 36
Study 26968329 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 36
Study 27097485 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria control knowledge awareness
Number of subjects: 800
Study 27097485 — intervention group
Group type: EXPERIMENTAL
Intervention: Media as a source of information
Number of subjects: 800
Study 27097485 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex, area, and education levels
Number of subjects: 800
Study 27097485 — intervention group
Group type: COMPARATOR
Intervention: Country vs Urban students
Number of subjects: 800
Study 27097485 — intervention group
Group type: COMPARATOR
Intervention: Secondary vs Primary school students
Number of subjects: 800
Study 23992935 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 4 g/day
Number of subjects: 229
Study 23992935 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 2 g/day
Number of subjects: 229
Study 23992935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 20336302 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of tamsulosin daily for 6 months
Number of subjects: 100
Study 20336302 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 100
Study 20336302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin after cessation of therapy
Number of subjects: 100
Study 20336302 — intervention group
Group type: COMPARATOR
Intervention: Placebo after cessation of therapy
Number of subjects: 100
Study 20336302 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin and placebo groups for peak urinary flow rate, PVR, and IIEF
Number of subjects: 100
Study 18762647 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weight-bearing
Number of subjects: 110
Study 18762647 — intervention group
Group type: COMPARATOR
Intervention: Non-weight-bearing
Number of subjects: 110
Study 16028524 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumo‐23
Number of subjects: 38
Study 16028524 — intervention group
Group type: EXPERIMENTAL
Intervention: Act‐HIB
Number of subjects: 38
Study 16028524 — intervention group
Group type: COMPARATOR
Intervention: Control group (not vaccinated)
Number of subjects: 38
Study 11917292 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic agents developed to ameliorate or prevent toxicities (specific agents not mentioned)
Number of subjects: 0
Study 11917292 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled, randomized phase II studies
Number of subjects: 0
Study 11917292 — intervention group
Group type: COMPARATOR
Intervention: Phase III studies of toxicity modifiers
Number of subjects: 0
Study 10070911 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose i.v. sodium ferric gluconate complex in sucrose (1.0 g)
Number of subjects: 88
Study 10070911 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose i.v. sodium ferric gluconate complex in sucrose (0.5 g)
Number of subjects: 88
Study 10070911 — intervention group
Group type: COMPARATOR
Intervention: Oral iron treatment
Number of subjects: 88
Study 10070911 — intervention group
Group type: COMPARATOR
Intervention: Control group (historically matched patients)
Number of subjects: 88
Study 7588508 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 g fat meal
Number of subjects: 10
Study 7588508 — intervention group
Group type: COMPARATOR
Intervention: 20 g fat meal
Number of subjects: 10
Study 2188410 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam rectally
Number of subjects: 94
Study 2188410 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g acetyl salicylic acid as effervescing tablets
Number of subjects: 94
Study 2188410 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 94
Study 2188410 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (diazepam, acetyl salicylic acid, placebo)
Number of subjects: 94
Study 6160032 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 20
Study 6160032 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 20
Study 31948926 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-variable model (IL-8, bicarbonate, protein C)
Number of subjects: 2737
Study 31948926 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-variable model (IL-8, bicarbonate, protein C, vasopressor use)
Number of subjects: 2737
Study 31948926 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinflammatory phenotype
Number of subjects: 2737
Study 31948926 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin treatment in HARP-2
Number of subjects: 2737
Study 29371130 — intervention group
Group type: EXPERIMENTAL
Intervention: OLA-iCPAP
Number of subjects: 967
Study 29371130 — intervention group
Group type: EXPERIMENTAL
Intervention: OLA-CPAP
Number of subjects: 967
Study 29371130 — intervention group
Group type: EXPERIMENTAL
Intervention: STD-CPAP
Number of subjects: 967
Study 29371130 — intervention group
Group type: COMPARATOR
Intervention: STD-O2
Number of subjects: 967
Study 27577978 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK cage (group A, n=34)
Number of subjects: 69
Study 27577978 — intervention group
Group type: COMPARATOR
Intervention: Autologous cage using lumbar spinous process and laminae (ACSP, group B, n=35)
Number of subjects: 69
Study 25122642 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of intravenous dexamethasone
Number of subjects: 58
Study 25122642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 23512440 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg/m2 beloranib
Number of subjects: 31
Study 23512440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 20666328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 microg x kg(‐1) + ketamine 0.5 mg x kg(‐1) + fentanyl 1.0 microg x kg(‐1) + atropine 0.5 mg (group FNT)
Number of subjects: 47
Study 20666328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 microg x kg(‐1) + ketamine 0.5 mg x kg(‐1) + alfentanil 5.0 microg x kg(‐1) + atropine 0.5 mg (group ALFNT)
Number of subjects: 47
Study 20666328 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 1.0 mg x kg(‐1) + atropine 0.5 mg (group Dolsin)
Number of subjects: 47
Study 17148931 — intervention group
Group type: COMPARATOR
Intervention: Constant Continuous Positive Airway Pressure (CPAP)
Number of subjects: 20
Study 17148931 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic Continuous Positive Airway Pressure (APAP)
Number of subjects: 20
Study 17148931 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP
Number of subjects: 20
Study 15925053 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucoadhesive vaginal gel (MVG, Miphil) 2.5 g daily for the first week and then every 3 days for 5 weeks
Number of subjects: 45
Study 15925053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 45
Study 15925053 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucoadhesive vaginal gel (MVG, Miphil)
Number of subjects: 45
Study 14700450 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release formulations of bupropion, paroxetine, and venlafaxine
Number of subjects: 0
Study 14700450 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release formulations of bupropion, paroxetine, and venlafaxine
Number of subjects: 0
Study 14700450 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (controlled-release)
Number of subjects: 0
Study 14700450 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (immediate-release)
Number of subjects: 0
Study 10552270 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-kg load carriage
Number of subjects: 22
Study 10552270 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-kg load carriage
Number of subjects: 22
Study 10552270 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-kg and 20-kg load carriage
Number of subjects: 22
Study 9505937 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU per day)
Number of subjects: 0
Study 9505937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8472631 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group participation (facilitated by investigator and diabetic nurse specialist, met fortnightly for 6 months)
Number of subjects: 61
Study 8472631 — intervention group
Group type: COMPARATOR
Intervention: Control group (no participation in support group)
Number of subjects: 61
Study 3523792 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (PZ) 50 mg twice daily
Number of subjects: 67
Study 3523792 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (CM) 400 mg twice daily
Number of subjects: 67
Study 3523792 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (PZ) 50 mg at night (maintenance)
Number of subjects: 67
Study 3523792 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (CM) 400 mg at night (maintenance)
Number of subjects: 67
Study 30115945 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-IF
Number of subjects: 60
Study 30115945 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-EF
Number of subjects: 60
Study 30115945 — intervention group
Group type: COMPARATOR
Intervention: Control-IF
Number of subjects: 60
Study 30115945 — intervention group
Group type: COMPARATOR
Intervention: Control-EF
Number of subjects: 60
Study 27299418 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw fixation
Number of subjects: 27
Study 27299418 — intervention group
Group type: COMPARATOR
Intervention: No screw fixation (Control)
Number of subjects: 27
Study 24664793 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims-based measure of antipsychotic polypharmacy (90-day concurrent use of ≥2 antipsychotics, allowing for a 32-day gap)
Number of subjects: 312
Study 24664793 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims-based measure definitions tested
Number of subjects: 312
Study 24664793 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance between claims and medical record-based categorization
Number of subjects: 312
Study 21722188 — intervention group
Group type: COMPARATOR
Intervention: Submerged healing (S)
Number of subjects: 127
Study 21722188 — intervention group
Group type: COMPARATOR
Intervention: Transmucosal healing (TM)
Number of subjects: 127
Study 21722188 — intervention group
Group type: COMPARATOR
Intervention: Both groups (S and TM)
Number of subjects: 127
Study 20712132 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol eardrops with 0.5% lidocaine
Number of subjects: 105
Study 20712132 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol eardrops with 2% lidocaine
Number of subjects: 105
Study 20712132 — intervention group
Group type: COMPARATOR
Intervention: Glycerol eardrops
Number of subjects: 105
Study 18359433 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (single session + daily practice tapes for one month)
Number of subjects: 150
Study 18359433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study 15997604 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced primary-care depression intervention
Number of subjects: 211
Study 15997604 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 211
Study 12721260 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF plus vincristine and prednisone
Number of subjects: 905
Study 12721260 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 905
Study 12721260 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 905
Study 10660814 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) combined with clonidine
Number of subjects: 24
Study 10660814 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine monotherapy
Number of subjects: 24
Study 10660814 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) monotherapy
Number of subjects: 24
Study 8860030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing devices embedded in the lingual surface of the appliance
Number of subjects: 40
Study 8860030 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-releasing acrylic polymer appliances
Number of subjects: 40
Study 1565455 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily levobunolol (0.5%)
Number of subjects: 20
Study 1565455 — intervention group
Group type: COMPARATOR
Intervention: Once-daily levobunolol (0.5%)
Number of subjects: 20
Study 2866119 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic phenoxybenzamine
Number of subjects: 41
Study 2866119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31251162 — intervention group
Group type: EXPERIMENTAL
Intervention: CPV case simulation-based measurement and feedback
Number of subjects: 107
Study 29358292 — intervention group
Group type: EXPERIMENTAL
Intervention: Oritavancin (1,200 mg intravenous single dose)
Number of subjects: 1959
Study 29358292 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (twice-daily intravenous for 7 to 10 days)
Number of subjects: 1959
Study 27342888 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Acupuncture Group (RAG)
Number of subjects: 78
Study 27342888 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham Acupuncture Group (SAG)
Number of subjects: 78
Study 27342888 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 78
Study 23697261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (15 days treatment)
Number of subjects: 90
Study 23697261 — intervention group
Group type: COMPARATOR
Intervention: Control group (GP2, not treated)
Number of subjects: 90
Study 23697261 — intervention group
Group type: COMPARATOR
Intervention: Control group (GP1, non-allergic)
Number of subjects: 90
Study 20571774 — intervention group
Group type: EXPERIMENTAL
Intervention: ‐1997T variant
Number of subjects: 1717
Study 20571774 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype 3 (‐1997T‐1663ins + 1245G)
Number of subjects: 1717
Study 19938924 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition
Number of subjects: 63
Study 19938924 — intervention group
Group type: COMPARATOR
Intervention: Nonalcohol condition
Number of subjects: 63
Study 19938924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypermasculine men
Number of subjects: 63
Study 17262007 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 14
Study 17262007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17262007 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 14
Study 17262007 — intervention group
Group type: COMPARATOR
Intervention: Two or more SGAs
Number of subjects: 14
Study 15042429 — intervention group
Group type: EXPERIMENTAL
Intervention: AC+CC genotype of AT1
Number of subjects: 114
Study 15042429 — intervention group
Group type: EXPERIMENTAL
Intervention: TT genotype of AGT
Number of subjects: 114
Study 15042429 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of hypertension
Number of subjects: 114
Study 15042429 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepregnancy BMI >= 25
Number of subjects: 114
Study 11305827 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lidocaine plus 10 microg sufentanil
Number of subjects: 20
Study 11305827 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lidocaine plus 10 microg sufentanil plus epinephrine 50 microg
Number of subjects: 20
Study 9029223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (IV) 1.3 g/kg
Number of subjects: 26
Study 9029223 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (PO) 1.3 g/kg
Number of subjects: 26
Study 9029223 — intervention group
Group type: COMPARATOR
Intervention: Artificially sweetened placebo (Asp) in 1 liter of water
Number of subjects: 26
Study 7705854 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim 320 mg/sulphamethoxazole 1600 mg by mouth for 2 days (TMPSMX)
Number of subjects: 517
Study 7705854 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 3 gm, probenicid 1 gm, and clavulanate 125 mg by mouth once (APC)
Number of subjects: 517
Study 7705854 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 3 gm, probenicid 1 gm, and clavulanate 125 mg by mouth once with doxycycline 100 mg BID for 7 days (APC-D)
Number of subjects: 517
Study 7705854 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 240 mg IM once (GENT)
Number of subjects: 517
Study 7705854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg by mouth once (CIPRO)
Number of subjects: 517
Study 7705854 — intervention group
Group type: COMPARATOR
Intervention: N/A (Control group not specified)
Number of subjects: 517
Study 3129938 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alcohol consumption (one beverage per day)
Number of subjects: 56
Study 3129938 — intervention group
Group type: COMPARATOR
Intervention: Abstention from alcohol
Number of subjects: 56
Study 29417831 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise (n=31), 8-week treatment protocol, 16 individual sessions, twice a week
Number of subjects: 60
Study 29417831 — intervention group
Group type: COMPARATOR
Intervention: Patient-education (n=29), group sessions, once a week
Number of subjects: 60
Study 26811126 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol beverage condition
Number of subjects: 161
Study 26811126 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage condition
Number of subjects: 161
Study 26811126 — intervention group
Group type: COMPARATOR
Intervention: Control beverage condition
Number of subjects: 161
Study 26811126 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional and alcohol-related cues
Number of subjects: 161
Study 26811126 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral picture cues
Number of subjects: 161
Study 26811126 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition priming
Number of subjects: 161
Study 25636328 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping for CYP2D6 with dosing advice communicated to the treating physician
Number of subjects: 0
Study 25636328 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study 25636328 — intervention group
Group type: EXPERIMENTAL
Intervention: External reference group of patients with extensive metabolizer genotype
Number of subjects: 0
Study 23622922 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 608
Study 23622922 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 608
Study 20067619 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention consisting of group educational sessions lasting a total of 10 hours
Number of subjects: 932
Study 20067619 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 932
Study 18360017 — intervention group
Group type: EXPERIMENTAL
Intervention: manidipine/delapril
Number of subjects: 158
Study 18360017 — intervention group
Group type: COMPARATOR
Intervention: olmesartan/hydrochlorothiazide
Number of subjects: 158
Study 20617907 — intervention group
Group type: EXPERIMENTAL
Intervention: IT‐18 thermocouples
Number of subjects: 18
Study 20617907 — intervention group
Group type: EXPERIMENTAL
Intervention: PT‐6 thermocouples
Number of subjects: 18
Study 20617907 — intervention group
Group type: EXPERIMENTAL
Intervention: IT‐21 thermocouples
Number of subjects: 18
Study 20617907 — intervention group
Group type: EXPERIMENTAL
Intervention: Datalogger electrothermometer
Number of subjects: 18
Study 20617907 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso‐Thermex calibrated from ‐50 degrees C to 50 degrees C
Number of subjects: 18
Study 20617907 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso‐Thermex calibrated from ‐20 degrees C to 80 degrees C
Number of subjects: 18
Study 16232015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure
Number of subjects: 12
Study 16232015 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 12439260 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative long leg standing radiograph
Number of subjects: 94
Study 12439260 — intervention group
Group type: COMPARATOR
Intervention: No preoperative long leg standing radiograph
Number of subjects: 94
Study 9673299 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg of OspA vaccine
Number of subjects: 10305
Study 9673299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10305
Study 8022625 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.075%
Number of subjects: 10
Study 8022625 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.125%
Number of subjects: 10
Study 8022625 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.25%
Number of subjects: 10
Study 8022625 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.5%
Number of subjects: 10
Study 8022625 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 10
Study 2730823 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine with 1 in 100,000 noradrenaline
Number of subjects: 40
Study 2730823 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 40